Clinical trials: Airflow Limitation
Chronic Obstructive Pulmonary Disease (COPD)
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
This study is to assess the safety and tolerability of two different doses of QVA149 and QAB149 in patients with moderate to severe airflow limitation.
- Trial name
- NCT01682863
- Testing
- QVA149, QAB149
- Where
- 86 sites in United States, Bulgaria and 5 more
- Volunteers
- 614 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
The aim of this First Time in Patient study is to obtain initial information on the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of repeat daily administration of danirixin in subjects with…
- Trial name
- NCT02130193
- Testing
- Danirixin
- Where
- 16 sites in United States, Germany
- Volunteers
- 102 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation
This study will assess the efficacy, safety and tolerability of indacaterol maleate/glycopyrronium bromide in patients with moderate to severe airflow limitation.
- Trial name
- NCT01712516
- Testing
- QVA149, QAB149, NVA237
- Where
- 95 sites in United States, Colombia and 7 more
- Volunteers
- 1,001 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of QVA149 in COPD Patients
The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while…
- Trial name
- NCT02487446
- Testing
- QVA149, Umeclidinium/vilanterol
- Where
- 58 sites in United States
- Volunteers
- 357 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Airflow Limitation in Cardiac Diseases in Europe
This is a cross-sectional, observational study, investigating the point prevalence of Airflow Limitation in current or former smokers with established ischemic heart disease.
- Trial name
- ALICE (NCT01485159)
- Testing
- Spirometry
- Where
- 15 sites in Belgium, France and 7 more
- Volunteers
- 3,000 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
The purpose of the study is to provide long term safety data of NVA237. This study will assess the safety and tolerability of a single dose strength of NVA237.
- Trial name
- NCT01697696
- Testing
- NVA237, Long-acting beta 2-agonist (LABA)
- Where
- 61 sites in United States
- Volunteers
- 511 people
- Sponsor
- Novartis Pharmaceuticals
Asthma-COPD Overlap Syndrome
A Non-interventional Study to Investigate the Current Situation of Asthma-COPD Overlap Syndrome in Patients Over Age 40 With Persistent Airflow Limitation in China
To investigate the distributions of the patients with ACOS, asthma and COPD over age 40 with chronic airflow limitation in China.
- Trial name
- NCT02600221
- Where
- 13 sites in China
- Volunteers
- 2,016 people
- Sponsor
- AstraZeneca
Respiratory (Chronic Obstructive Pulmonary Disease)
Study for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics
Chronic Obstructive Pulmonary Disease (COPD) is a global health concern, associated with structural lung abnormalities causing persistent airflow limitation (AL) and often result from cigarette smoking.
- Trial name
- ALSAC (NCT07315958)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Alpha 1-Antitrypsin Deficiency
Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"
The goal of this clinical trial is to learn if AAT for inhalation, at a dose of 80 mg/day can slow the progression of lung disease in people who have lung disease caused by severe genetic deficiency in Alpha 1 Antitrypsin (AATD).
- Trial name
- InnovAATe (NCT04204252)
- Testing
- Alpha 1-Antitrypsin
- Where
- 9 sites in Belgium, Finland and 4 more
- Volunteers
- 98 people
- Sponsor
- Kamada, Ltd.
Chronic Obstructive Pulmonary Disease
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
Study is to show that QVA149 is superior to the standard of care, fluticasone/salmeterol, in patients with moderate to severe airflow limitation.
- Trial name
- NCT01860066
- Testing
- QVA149, fluticasone/salmeterol
- Where
- 31 sites in Argentina, Belgium and 3 more
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS
This study is to evaluate if add-on treatment with inhaled NVA237 (50 µg) once daily (o.d.) via single-dose dry-powder inhaler (SDDPI) further improves lung function and health status and is well tolerated compared to placebo in…
- Trial name
- GLOW8 (NCT01757015)
- Testing
- NVA237
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.
This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to severe airflow limitation.
- Trial name
- NCT01727141
- Testing
- QVA149, QAB149, NVA237
- Where
- 143 sites in United States, Canada and 6 more
- Volunteers
- 1,042 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease, COPD
Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients
The study is a multicenter, randomized, 2-period, open-label, two arm, cross-over study to show the superior effect of a 4 week treatment each with QVA149 versus tiotropium on lung function.
- Trial name
- FAVOR (NCT02125734)
- Testing
- QVA149, Tiotropium
- Where
- 18 sites in Germany
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
Study is to show that QVA149 is superior to the standard of care, fluticasone/salmeterol, in patients with moderate to severe airflow limitation
- Trial name
- NCT01834885
- Testing
- QVA149, fluticasone/salmeterol
- Where
- 29 sites in Austria, Germany
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation
The study will assess the long-term safety of the fixed combination product QVA149 versus placebo and a standard of care treatment (tiotropium) in Chronic Obstructive Pulmonary Disease (COPD) patients with moderate to severe…
- Trial name
- NCT01610037
- Testing
- QVA149, Tiotropium
- Where
- 116 sites in Argentina, Colombia and 15 more
- Volunteers
- 1,215 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.
The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while…
- Trial name
- NCT02487498
- Testing
- QVA149, Umeclidinium/vilanterol
- Where
- 53 sites in United States
- Volunteers
- 355 people
- Sponsor
- Novartis Pharmaceuticals